investors

Press Releases

DateTitle and SummaryView
August 6, 2015
ICT-107 Phase 3 Registration Trial to Begin Late Third Quarter or Early Fourth Quarter 2015; Stem-to-T-cell Program Advancing
ImmunoCellular Therapeutics Announces Second Quarter 2015 Financial Results
July 23, 2015
LOS ANGELES , July 23, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report financial results for the second quarter 2015 on Thursday, August 6, 2015 . The Company also plans to hold a conference call and webcast on
ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015
July 6, 2015
LOS ANGELES , July 6, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma.
ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma
June 29, 2015
LOS ANGELES , June 29, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos , Chief Executive Officer of ImmunoCellular , will present a corporate overview and business update at the Cantor Fitzgerald Inaugural Healthcare
ImmunoCellular Therapeutics to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8th
June 22, 2015
LOS ANGELES , June 22, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) announced an agreement with Pure MHC, an Emergent Technologies portfolio company, for development of a novel assay for quality control that will be an important component of
ImmunoCellular Therapeutics Establishes Agreement with Pure MHC for Novel Quality Control Assay for ICT-107 Phase 3 Registrational Trial
June 15, 2015
LOS ANGELES , June 15, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) announced the selection of PCT, LLC , a subsidiary of Caladrius Biosciences, Inc. ("Caladrius") (NASDAQ:CLBS), as the US manufacturer for ImmunoCellular's ICT-107 phase 3
ImmunoCellular Therapeutics Enters into Manufacturing Agreement with PCT LLC, a Caladrius Company, for US Production of ICT-107 for Phase 3 Registration Trial
May 19, 2015
LOS ANGELES , May 19, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos , Chief Executive Officer of ImmunoCellular , will present a corporate overview and business update at the Marcum MicroCap Conference on Thursday,
ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on May 28th
May 11, 2015
Phase 3 Registration Trial for ICT-107 to Initiate in Second Half of 2015; Financial Results Conference Call to be Held on May 12, 2015
ImmunoCellular Therapeutics Announces First Quarter 2015 Financial Results
May 11, 2015
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation NEW YORK , May 11, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC), today announced that the May 7 presentation
ImmunoCellular Therapeutics Presentation Now Available for On-Demand Viewing
May 5, 2015
Company invites individual and institutional investors to attend interactive real-time virtual roadshow  NEW YORK , May 5, 2015 /CNW/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos , President and Chief Executive Officer, will present
ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved